For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback